OCTOBER 19–21, 2021

CME jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.
Welcome

Welcome to the 2021 AACI/CCAF Annual Meeting! This three-day, virtual meeting convenes AACI members with national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges.

Since our 2020 annual meeting, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine joined AACI, bringing our number of cancer center members to 103, and Fulgent Genetics joined the AACI Corporate Roundtable. I’d like to extend a warm welcome to our new members.

AACI also welcomes three new members to the Board of Directors: Drs. Marcia Cruz-Correa, Ruben A. Mesa, and Robert H. Vonderheide. Dr. Robert A. Winn began his term as AACI vice president/president-elect on June 1, with Dr. Joann Sweasy appointed to fill the remainder of his term as a regular board member. We extend our appreciation to outgoing board members, Drs. Leonidas C. Platanias, Randall F. Holcombe, and Thomas P. Loughran, Jr., for their service. AACI would also like to recognize Jeff A. Walker for seven years of service as treasurer, and welcome David M. Gosky to the role. Finally, I hope you’ll join me in congratulating Dr. Karen E. Knudsen on her brief tenure as AACI president. Under her leadership, AACI made important progress in understanding and mitigating health disparities at AACI cancer centers.

We are pleased to recognize the research achievements of Dr. Judy E. Garber this year. In addition to receiving AACI’s Distinguished Scientist Award, Dr. Garber will present a keynote on her research on the treatment of triple-negative or basal-like breast cancer. We will also honor Sidney and Caroline Kimmel with the AACI Champion for Cures Award in recognition of their philanthropic support of the Sidney Kimmel Cancer Center at Jefferson Health. AACI Vice President/President-elect Dr. Robert A. Winn will receive the inaugural AACI Cancer Health Equity Award in recognition of his exceptional leadership in promoting health equity and advocating for diversity and inclusion. And AACI will also honor Dr. Robert T. Croyle for his years of service to the National Cancer Institute.

This year’s meeting program was jointly formulated by AACI and the Cancer Center Administrators Forum (CCAF). I would like to offer a special thanks to Dr. Winn, who chaired the program committee. The program features panel discussions on topics including the National Cancer Act at 50; telehealth and cancer care at home; and data science and artificial intelligence. AACI President, Dr. Caryn Lerman, will introduce her presidential initiative, which is already well underway and will focus on developing the cancer leadership pipeline with an emphasis on diversity.

I am thankful for the hard work and expertise of the 2021 AACI/CCAF Annual Meeting Program Committee and AACI staff who helped make this meeting possible. I look forward to meeting with you—in person—in Kansas City next year!

Sincerely,
Jennifer W. Pegher
Executive Director

Program Committee

Chair: Robert A. Winn, MD
VCU Massey Cancer Center

S. Gail Eckhardt, MD, FASCO
Livestrong Cancer Institutes
The University of Texas at Austin Dell Medical School

Matthew Huesser, MBA, DBA
Sidney Kimmel Cancer Center at Jefferson Health

Caryn Lerman, PhD
USC Norris Comprehensive Cancer Center

Jennifer W. Pegher, MA
Association of American Cancer Institutes

Anil K. Rustgi, MD
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

Julie C. Schaum, MS
Vanderbilt-Ingram Cancer Center

Katherine Shumate, MPA, CCRP
UCSF Helen Diller Family Comprehensive Cancer Center

Cornelia Ulrich, PhD, MS
Huntsman Cancer Institute
University of Utah

Robert H. Vonderheide, MD, DPhil
Abramson Cancer Center of the University of Pennsylvania

Jane Welter, MBA
Mayo Clinic Cancer Center

Meeting Access and Social Media

To access annual meeting sessions and presentations and find exhibitors and attendees, visit the meeting website at https://cvent.me/Vna4nn.

To access the website, log in with your name and email from registration. You will receive a 6-digit verification code at this email address or the mobile phone you provided at registration. Enter your 6-digit code and click “Log In.”

Twitter: @AACI_Cancer
Facebook: AACICancer
Hashtag: #AACI2021
Agenda

All sessions are in eastern time and subject to change.

Tuesday, October 19

10:00 am Exhibits Open

10:00 am Welcome and AACI Business Meeting

Dr. Caryn Lerman
USC Norris Comprehensive Cancer Center

Jennifer W. Pegher
Association of American Cancer Institutes

Katherine Shumate
UCSF Helen Diller Family Comprehensive Cancer Center

Jeff A. Walker
Roswell Park Comprehensive Cancer Center

Dr. Robert A. Winn
VCU Massey Cancer Center

10:35 am Envisioning New Modalities in Cancer Care: Telehealth and Cancer Care at Home

COVID-19 has fast-tracked the use of telehealth and methods for delivering cancer care to patients at home. This session will highlight demonstrated successes, challenges, and opportunities in the post-pandemic world.

Co-moderator: Dr. Cornelia Ulrich
Huntsman Cancer Institute, University of Utah

Co-moderator: Jane Welter
Mayo Clinic Cancer Center

Dr. Kathi Mooney
Huntsman Cancer Institute, University of Utah

Dr. Tuya Pal
Vanderbilt-Ingram Cancer Center

Dr. David Smith
University of Michigan Rogel Cancer Center

11:40 am COVID-19’s Impact on Cancer Centers, Patients, Practitioners, and Communities

While the pandemic has adjusted approaches to cancer screening and survivorship and added COVID infection to the array of treatment concerns, it has also highlighted the need for psychosocial support for the cancer center workforce, preserving the community of researchers, and caring for the caregivers.

Co-moderator: Dr. Anil K. Rustgi
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

Co-moderator: Jane Welter
Mayo Clinic Cancer Center

Dr. Barbara Jones
Livestrong Cancer Institutes
The University of Texas at Austin
Dell Medical School

Dr. Andrew B. Lassman
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

Dr. Mariana Carla Stern
USC Norris Comprehensive Cancer Center

12:40 pm Visit With Exhibitors

1:10 pm Break

1:25 pm Computational Oncology: Applying Data Science and Artificial Intelligence to Cancer Prevention and Outcomes

Data science offers a variety of tools and techniques for understanding the behavior of cancerous cells, developing multi-level models of cancer risk or outcomes that incorporate social determinants of health, and cancer therapy development and delivery.

Co-moderator: Dr. Caryn Lerman
USC Norris Comprehensive Cancer Center

Co-moderator: Katherine Shumate
UCSF Helen Diller Family Comprehensive Cancer Center

Dr. Riyue Bao
UPMC Hillman Cancer Center

Dr. Stacey D. Finley
USC Norris Comprehensive Cancer Center

Dr. Saeed Hassanpour
Dartmouth-Hitchcock Norris Cotton Cancer Center
Agenda

2:30 pm 9th Annual AACI Physician Clinical Leadership Initiative (PCLI) Meeting: Cancer Care Across the Lifespan
The PCLI meeting will focus on the care and treatment of pediatric, adult, and geriatric patients, and will address the needs of each cohort. Panelists will touch on topics including biologic markers of aging, geriatric-driven interventions, and the importance of advocates and palliative care for patients and families. They will also analyze how cancer treatment is administered, how it affects different age groups, and how it can be improved.

Moderator: Dr. Andrew Chapman
Sidney Kimmel Cancer Center at Jefferson Health

Dr. Doug Fair
Huntsman Cancer Institute, University of Utah

Dr. Tanyanika Phillips
City of Hope Comprehensive Cancer Center

Dr. Ashley Rosko
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

3:35 pm Connecting Research Stakeholders With an Integrated Technology Ecosystem
Vendor Presentation: Advarra

In this session, Stuart Cotter, director of product management at Advarra, will outline the need and highlight Advarra’s plans for an integrated suite of technology solutions connecting sites, sponsors, and clinical research organizations (CROs). Cotter will summarize the need for site-owned enterprise technology and the burden imposed by sponsor systems. He’ll then outline a new approach, leveraging the enterprise technology research sites already own to exchange data with sponsors and CROs, greatly reducing the burden on sites while accelerating the pace of study start-up and trial conduct.

Stuart Cotter
Advarra

Wednesday, October 20

10:00 am AACI 2021 Distinguished Scientist Award – Opening Keynote
Introduction and Presentation of Award
Dr. Laurie H. Glimcher
Dana-Farber Cancer Institute, Harvard Medical School

Dr. Judy E. Garber
Dana-Farber Cancer Institute, Harvard Medical School

11:05 am Reimagining Clinical Trials
Cancer clinical trials must adapt to the changing needs of patients and opportunities arising through the COVID-19 pandemic. Strategies include diversifying the clinical trials workforce, targeting community outreach efforts, and formulating new approaches to treatment trials, home health care, and remote trials.

Co-moderator: Dr. S. Gail Eckhardt
Livestrong Cancer Institutes
The University of Texas at Austin
Dell Medical School

Co-moderator: Dr. Matthew Huesser
Sidney Kimmel Cancer Center at Jefferson Health

Dr. David Gerber
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

Cheryl Jernigan
The University of Kansas Cancer Center

Dr. Colin D. Weekes
Massachusetts General Hospital
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:05 pm</td>
<td>Champion for Cures Award</td>
<td>Introduction and Presentation of Award</td>
</tr>
<tr>
<td></td>
<td>Dr. Karen E. Knudsen</td>
<td>American Cancer Society</td>
</tr>
<tr>
<td></td>
<td>Sidney and Caroline Kimmel</td>
<td></td>
</tr>
</tbody>
</table>
Update on the NCI Cancer Centers Program
Dr. Henry Ciolino will lead a discussion about the National Cancer Institute's (NCI) goals for the national cancer research enterprise; standards for developing new and better approaches to preventing, diagnosing, and treating cancer; and the optimal distribution of limited federal cancer research funds at AACI cancer centers.

Dr. Henry Ciolino
National Cancer Institute

Derisking the Move to eConsent as a Cancer Institute
Vendor Presentation: Florence

Session not CME accredited

eConsent is becoming an integral part of digital research, and cancer institutes need a technology action plan to make the transition successfully and compliantly. In this session, participants will learn how Florence is developing eConsent with numerous cancer institutes, as well as what to look for when evaluating eConsent software.

Blake Adams
Florence

Andrea Bastek
Florence

The National Cancer Act at 50: Reflecting on the Past, Envisioning the Future
This year marks the 50th anniversary of the National Cancer Act, which established the National Cancer Institute's robust network of cancer centers and strengthened cancer clinical research. Panelists will touch on the last 50 years of progress while discussing potential for the future.

Co-moderator: Dr. Robert H. Vonderheide
Abramson Cancer Center of the University of Pennsylvania

Co-moderator: Julie C. Schaum
Vanderbilt-Ingram Cancer Center

Dr. Otis W. Brawley
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Dr. Robert T. Croyle
Division of Cancer Control and Population Sciences
National Cancer Institute

Dr. Michelle M. Le Beau
The University of Chicago Medicine Comprehensive Cancer Center

Reducing Cancer Disparities: How to Ensure Durable Solutions
Cancer disparities manifest in many forms, from racism in prevention, screening, and genetic testing to lack of diversity in clinical trials. Increasing the diversity of the cancer center workforce and research portfolio, instituting health equity report cards, enhancing trust among community members, and the trustworthiness of cancer centers are among the targeted measures that panelists will discuss as possible paths to reducing cancer disparities.

Moderator: Dr. Robert A. Winn
VCU Massey Cancer Center

Dr. Lucile Adams-Campbell
Georgetown Lombardi Comprehensive Cancer Center

Dr. Chyke A. Doubeni
Mayo Clinic Cancer Center

Dr. Chanita Hughes Halbert
USC Norris Comprehensive Cancer Center

Visit With Exhibitors
Agenda

12:35 pm  Break

12:55 pm  Nothing’s as Constant as Change: Understanding New CCSG Guidelines
Optimal compliance with National Cancer Institute Cancer Center Support Grant (CCSG) guidelines will be explored, with particular focus on revisions to the Funding Opportunity Announcement, new diversity and inclusion reporting requirements, and virtual site visits. Panelists will review the practical implications of preparing a CCSG competing renewal and discuss best practices for both freestanding and matrix cancer centers.

Moderator: Katherine Shumate
UCSF Helen Diller Family Comprehensive Cancer Center

Julie Brabbs
University of Michigan Rogel Cancer Center

Dr. Matthew Huesser
Sidney Kimmel Cancer Center at Jefferson Health

Dr. Wendy Law
Fred Hutchinson Cancer Research Center

2:00 pm  NCI Director’s Report
An expanding roster of approved cancer drugs and devices, declining mortality, and a dramatic increase in grant applications to the National Cancer Institute (NCI) point to a remarkable era in cancer research. Dr. Norman E. Sharpless will highlight the NCI’s dedication to investing in research infrastructure at the institutions where investigators make their key discoveries, as well as its careful planning for budget uncertainty to balance the increasing demand for new grants with previous commitments. Other likely topics include cancer in the Biden administration, the 50th anniversary of the National Cancer Act, health disparities research and efforts to advance health equity, and attracting and retaining a diverse cancer researcher workforce.

Dr. Norman E. Sharpless
National Cancer Institute

Continuing Medical Education

Joint Providership Statement
Jointly provided by the American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI).

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research (AACR) and Association of American Cancer Institutes (AACI). The AACR is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Credit Designation Statement
AACR has designated this internet live activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete the online CME Request for Credit Survey by Thursday, December 2, 2021. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the conference website and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Continuing Medical Education

Statement of Educational Need, Target Audience, and Learning Objectives

Despite enormous progress in the field, cancer continues to be a global public health challenge, accounting for one in every six deaths that occur around the world. In the United States alone, it is predicted that more than 600,000 people will die from some form of cancer in 2021, making it the second most common cause of death after heart disease.

With the quickening pace of discoveries in basic, translational, and clinical research, the battle against cancer is rapidly moving forward. This is due in large part to the advent of new technologies, such as liquid biopsies, and our growing knowledge about how to activate the immune system to develop new immunotherapies. However, understanding and combating cancer requires leadership armed with up-to-date information about advanced technology and proven methods for its implementation. The meeting program highlights issues associated with the successful operation of leading academic cancer centers, including applying the latest best practices to clinical trial operations; applying data science and artificial intelligence to cancer prevention; integrating telehealth and cancer care at home; managing COVID-19’s impact; and reducing cancer disparities. Meeting sessions will examine both current practices and novel approaches to these shared challenges and opportunities.

Researchers, physicians, and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to faculty and staff at their cancer centers.

After participating in this CME activity, physicians should be able to describe and discuss:

1. Adapting clinical trials to the changing needs of patients and diversifying the clinical trials workforce
2. Various data science tools and techniques for understanding the behavior of cancerous cells and ways to develop multi-level models of cancer risk or outcomes
3. Successes, challenges, and opportunities related to the implementation of telehealth and cancer care at home, especially in a post-pandemic environment
4. COVID-19’s impact on cancer centers, patients, practitioners, and communities, particularly the need for psychosocial support for the cancer center workforce and supporting the community of researchers and caregivers
5. Reducing cancer disparities in its many manifestations—e.g., lack of diversity in clinical trials—and its domains of exposure as it relates to cancer center service delivery, including prevention, screening, and genetic testing
6. Compliance with current National Cancer Institute (NCI) Cancer Center Support Grant guidelines
7. Research at basic science cancer centers
8. The NCI’s priorities, policies, strategies, and goals for the national cancer research enterprise, and their relationship to academic cancer centers

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference and on the website.

Acknowledgment of Financial or Other Support

This activity is supported by Professional Educational Grants and will be disclosed at the meeting.

Questions about CME?

Please contact the Office of CME at 215-440-9300 or cme@aacr.org.
## Awardee Profiles

### 2021 AAI Distinguished Scientist Award

**Judy E. Garber, MD, PhD**  
**Dana-Farber Cancer Institute**  
**Harvard Medical School**

Dr. Judy Garber is chief of the Division of Cancer Genetics and Prevention at the Dana-Farber Cancer Institute. AACI is recognizing Dr. Garber, a professor of medicine at Harvard Medical School, for her breakthrough research on the treatment of triple-negative or basal-like breast cancer, the most common form in women with BRCA1 mutations.

She is a member of the National Academy of Medicine, past member of the National Cancer Institute Board of Scientific Counselors, and the American Society for Clinical Investigation, and is the past president of the American Association for Cancer Research. She was appointed by President Obama to serve a six-year term on the National Cancer Advisory Board, and in 2013 she was elected to the Institute of Medicine.

Dr. Garber’s recent investigations of germline and somatic genetic markers to predict response to targeted therapies in breast cancer patients are impacting clinical practices everywhere. Other therapies are being studied to prevent cancer in women with a heightened genetic risk for certain forms of the disease.

Dr. Garber attended Yale School of Medicine, receiving her MD/MPH in 1981. She completed her residency in internal medicine and fellowship in hematology at Brigham and Women’s Hospital, and her fellowship in medical oncology at the Dana-Farber Cancer Institute, both in Boston.

Recent AACI Distinguished Scientist honorees include Dana-Farber’s own Dr. William Kaelin, Jr., as well as Drs. Douglas Lowy, James Allison, Lewis Cantley, Brian Druker, Mary-Claire King, and Margaret R. Spitz.

---

### CME-Approved Sessions Worksheet

<table>
<thead>
<tr>
<th>Date</th>
<th>Time (eastern)</th>
<th>Session Title</th>
<th>Approved Credits</th>
<th>Credits Claimed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday 10/19/2021</td>
<td>10:35 – 11:35 am</td>
<td>Envisioning New Modalities in Cancer Care: Telehealth and Cancer Care at Home</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:40 am – 12:40 pm</td>
<td>COVID-19’s Impact on Cancer Centers, Patients, Practitioners, and Communities</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:25 – 2:25 pm</td>
<td>Computational Oncology: Applying Data Science and Artificial Intelligence to Cancer Prevention and Outcomes</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:30 – 3:30 pm</td>
<td>9th Annual AACI Physician Clinical Leadership Initiative (PCLI) Meeting: Cancer Care Across the Lifespan</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum Approved Credits for 10/19/21</strong></td>
<td><strong>4.0</strong></td>
<td><strong>Total:</strong></td>
<td></td>
</tr>
<tr>
<td>Wednesday 10/20/2021</td>
<td>10:00 – 11:00 am</td>
<td>AACI 2021 Distinguished Scientist Award – Opening Keynote</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:05 am – 12:05 pm</td>
<td>Reimagining Clinical Trials</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:30 – 1:15 pm</td>
<td>AACI Presidential Initiatives</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:25 – 3:25 pm</td>
<td>Overview of the Basic Science Centers</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3:30 – 4:30 pm</td>
<td>Update on the NCI Cancer Centers Program</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum Approved Credits for 10/20/21</strong></td>
<td><strong>4.75</strong></td>
<td><strong>Total:</strong></td>
<td></td>
</tr>
<tr>
<td>Thursday 10/21/2021</td>
<td>10:00 – 11:00 am</td>
<td>The National Cancer Act at 50: Reflecting on the Past, Envisioning the Future</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:05 am – 12:05 pm</td>
<td>Reducing Cancer Disparities: How to Ensure Durable Solutions</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:55 – 1:55 pm</td>
<td>Nothing’s as Constant as Change: Understanding New CCSG Guidelines</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:00 – 3:00 pm</td>
<td>NCI Director’s Report</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum Approved Credits for 10/21/21</strong></td>
<td><strong>4.0</strong></td>
<td><strong>Total:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum CME Credits Approved</strong></td>
<td><strong>12.75</strong></td>
<td><strong>Total:</strong></td>
<td></td>
</tr>
</tbody>
</table>
Sidney and Caroline Kimmel have been selected to receive the 2021 AACI Champion for Cures Award, which recognizes transformational philanthropy that advances our shared vision of a future without cancer.

Over the past 25 years, Sidney and Caroline Kimmel have changed the course of cancer research and care in Philadelphia and across the nation. Since 1994, the Kimmels have given nearly $600 million for cancer research. This included a gift of $10 million to Thomas Jefferson University to name its cancer center, igniting a five-fold growth in the number of its investigators and establishing a premier program in translating breakthroughs and treatments. Because of the Kimmels, Jefferson has been a Philadelphia-area leader in oncology research, patient treatment, and education services.

Sidney Kimmel has remained actively engaged in the strategic vision and growth of the Sidney Kimmel Cancer Center (SKCC). He helped recruit luminary talent to the faculty and lent his wisdom to the center’s NCI-designation renewal in 2018. Today, SKCC is home to over 500 clinical employees. Along with his wife, Caroline, Kimmel helped establish SKCC’s first formal advisory council, comprised of 17 prominent leaders in business, health care, law, innovation, media, and philanthropy. Caroline Kimmel serves as a member of the Sidney Kimmel Cancer Center Advisory Council. The Kimmels’ giving has inspired others by providing $12 million in matching funds to create eight endowed professorships and 31 endowed scholarships. This includes giving the $70 million anchor gift for the Caroline Kimmel Biomedical Research Building, which will position SKCC’s research enterprise for decades to come.

The Champion for Cures Award was established as an annual award in 2018 to recognize philanthropic support of AACI cancer centers.

Robert A. Winn, MD
VCU Massey Cancer Center

AACI is honoring Dr. Robert A. Winn with the inaugural AACI Cancer Health Equity Award. Dr. Winn is AACI’s vice president/president-elect and director of VCU Massey Cancer Center.

Dr. Winn is being recognized for his passionate commitment to improving health equity and his significant positive impact on cancer care in Virginia. Driven by a belief that community engagement is a central component of population health management, Dr. Winn promotes services that reflect the unique needs and values of the populations Massey serves. He provides direction for the VCU Massey Office of Health Equity and Disparities Research, which offers a wide variety of health education programming, screenings, and resources for the public.

In addition to his work in the Massey catchment area, Dr. Winn is at the forefront of addressing health disparities, promoting health equity, and advocating for diversity and inclusion in cancer care at the national level. He currently serves as a principal investigator on several community-based projects funded by the National Institutes of Health and National Cancer Institute, including the All of Us Research Program. He has received national and international acclaim for his efforts to empower underserved patient populations, improve health care delivery, and ensure equal access to cancer care.

Dr. Winn will also oversee the Diversity in Clinical Trials Career Development Program, a partnership with National Medical Fellowships and Bristol Myers Squibb Foundation that seeks to advance clinical trial diversity and improve access to quality health care in underserved patient populations in the U.S., while developing a more diverse medical workforce.
Exhibitors

The American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI) express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

Advarra
Advarra advances the way clinical research is conducted: bringing life sciences companies, CROs, research sites, investigators, and academia together at the intersection of safety, technology, and collaboration. With trusted IRB and IBC review solutions, innovative technologies, experienced consultants, and deep-seated connections across the industry, Advarra provides integrated solutions that safeguard trial participants, empower clinical sites, ensure compliance, and optimize research performance. Advarra is advancing clinical trials to make them safer, smarter, and faster. For more information, visit advarra.com.

Caris Life Sciences®
Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assess DNA, RNA, and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia, and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).

ECG Management Consultants, a Siemens Healthineers Company
With knowledge and expertise built over the course of nearly 50 years, ECG is a national consulting firm that is leading health care forward. ECG offers a broad range of strategic, financial, operational, and technology-related consulting services to providers, building multidisciplinary teams to meet each client’s unique needs — from discrete operational issues to bigger-picture strategic and financial challenges. ECG is an industry leader, offering specialized expertise to hospitals, health systems, medical groups, academic medical centers, children’s hospitals, ambulatory surgery centers, and health care payers. Part of Siemens Healthineers’ global enterprise services practice, ECG’s subject matter experts deliver smart counsel and pragmatic solutions. ecgmc.com

Florence
Florence is the leading platform for remote connectivity and electronic document workflow management in clinical research. It is considered the industry standard, with more than 8,500 research sites, sponsors, and CROs in 34 countries collaborating on its network. Florence advances clinical trials through software for managing document and data flow between research sites and sponsors. Florence solutions foster 25 percent faster start-up time and 40 percent reduced document cycle time, among other benefits. To learn about advancing research through collaboration, visit florencehc.com.

Huron
Huron’s Cancer Center Practice is composed of leaders with 20-plus years of frontline experience in cancer centers. Huron’s deep understanding of the National Cancer Institute (NCI) landscape and firsthand knowledge of best practices will facilitate improvement of your center’s performance across multiple dimensions by tailoring approaches and solutions to your center’s goals, issues, and organizational environment. Huron has partnered with institutions across the country in supporting the development of a vibrant research enterprise, enhancing clinical research operations, streamlining research administration, providing strategic planning guidance, and preparing for NCI designation. huronconsultinggroup.com

nCoup
nCoup provides innovative cloud solutions that address operational needs of organizations conducting clinical research. nCoup recently launched nCartes, the next-generation EHR to EDC clinical data transport platform that enables sites and sponsors to harness electronic medical records to populate EDC systems and fulfill clinical trials. nCartes has been proven to reduce the time and cost of study data entry on some cancer clinical trials by 50 percent or more. nCoup leverages nCoup’s extensive and deep EHR integration and clinical trials software expertise to deliver nCartes. nCoup, Inc. is privately held with headquarters in Fremont, California. For more information on nCoup, please visit ncoup.com. For more information on nCartes, please visit ncartes.ncoup.com.

The Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. SITC is a 501(c)(3) not-for-profit medical professional society of more than 4,650 influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives, and industry leaders dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations, and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community. Hosting educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. sitcancer.org/home
Exhibitors

Veeva
Veeva offers a suite of applications built specifically for research sites and institutions with connectivity to sponsors and patients to reduce complexity and administrative burden. Veeva Systems Inc. is the leader in cloud-based software for the global clinical research industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,100 customers, ranging from the world’s largest pharmaceutical companies to emerging investigative sites. Learn more at sites.veeva.com.

WCG
WCG’s Managed Research Solutions empower high-performing, competitive research programs by transforming clinical research – supporting more trials, more patients, and more time for a patient-centric approach. WCG offers a suite of purpose-built services and robust technology designed to optimize your research program. Decrease study start-up timelines by 37 percent, increase enrollment by 39 percent, and boost financial results by 21 percent. Our flexible, tailored approach enhances efficiency while ensuring quality and compliance. It’s your research program, with our expert support. wcgclinical.com

WellSky®
WellSky is a technology company leading the movement for intelligent, coordinated care worldwide. Next-level software, analytics, and services power better outcomes and lower costs for stakeholders across the health and community care continuum. In today’s value-based care environment, WellSky helps providers, payers, health systems, and community organizations solve tough challenges, improve collaboration for growth, harness the power of data analytics, and achieve better outcomes by further connecting clinical and social care. Health Care Software Solutions | WellSky®

Support

Acknowledgment of Commercial Support
The American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI) express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:
- Astellas
- GlaxoSmithKline (GSK)
- Novartis
- Pfizer
- Varian Medical Systems

Acknowledgment of Programmatic Support
AACI gratefully acknowledges the following organizations for providing program and exhibit support:
- Advarra
- Caris Life Sciences®
- Ciox Health
- Complion
- ECG Management Consultants
- Florence
- Huron
- nCoup
- Patient Resource
- The Society for Immunotherapy of Cancer (SITC)
- UHealth Miami
- Veeva
- WCG
- WellSky®

Support as of October 13, 2021
<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Company</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lucie</td>
<td>Adams-Campbell</td>
<td>Georgetown Lombardi Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Niyet</td>
<td>Bob</td>
<td>UPMC Hillman Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Rohit</td>
<td>Bhargava</td>
<td>Cancer Center at Illinois</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Julie</td>
<td>Brabbs</td>
<td>University of Michigan Rogel Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Otis</td>
<td>Brawley</td>
<td>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University</td>
<td>Genentech/Roche, Incyte, Genentech/Roche, Incyte,</td>
<td>A,C,H,S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Andrew</td>
<td>Chapman</td>
<td>Sidney Kimmel Cancer Center at Jefferson Health</td>
<td>Roche, AUC, Therapeutics</td>
<td>C</td>
<td>Speaker</td>
</tr>
<tr>
<td>Henry</td>
<td>Collino</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Robert</td>
<td>Covey</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Chyke</td>
<td>Doubeni</td>
<td>Mayo Clinic Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Balk</td>
<td>Eichhardt</td>
<td>Livestrong Cancer Institutes, The University of Texas at Austin</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Douglas</td>
<td>Fair</td>
<td>Huntsman Cancer Institute, University of Utah</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Stacey</td>
<td>Finley</td>
<td>USC Norris Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Judy</td>
<td>Garber</td>
<td>Dana-Farber Cancer Institute, Harvard Medical School</td>
<td>Myriad Genetics, AstraZeneca, AmbrinGenetics, Invitae Genetics, Helix Genetics</td>
<td>G,O,A,C</td>
<td>Speaker</td>
</tr>
<tr>
<td>David</td>
<td>Gerber</td>
<td>Simmons Comprehensive Cancer Center, UT Southwestern Medical Center</td>
<td>Gilead Pharmaceuticals, Janssen, BelGene, Karyopharm, AstraZeneca</td>
<td>A,G,S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Steed</td>
<td>Hassanpour</td>
<td>Dartmouth-Hitchcock Norris Cotton Cancer Center</td>
<td>ViewSla</td>
<td>O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jane</td>
<td>Hofacker</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Matthew</td>
<td>Huesser</td>
<td>Sidney Kimmel Cancer Center at Jefferson Health</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Chantiza</td>
<td>Hughes Halbert</td>
<td>USC Norris Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Cheryl</td>
<td>Jennings</td>
<td>The University of Kansas Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Barbara</td>
<td>Jones</td>
<td>Livestrong Cancer Institutes, The University of Texas at Austin</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Karen</td>
<td>Knudtian</td>
<td>American Cancer Society</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Andrew</td>
<td>Lasman</td>
<td>Herbert Irving Comprehensive Cancer Center/Columbia University</td>
<td>&quot;Genentech/Roche, Milenium, Pfizer, Astera Zenaxis, Novartis, RXD, Karyopharm, Abiove, Kadyon, Bionica, Biokine, Ebelex, Durable, Sapience, Vivactis Oncology, MJH Holdings/Physician's Education Resource&quot;</td>
<td>G,H,C,A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Wendy</td>
<td>Law</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Michelle</td>
<td>Le Beau</td>
<td>The University of Chicago Medicine Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Caryn</td>
<td>Lerman</td>
<td>USC Norris Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Kati</td>
<td>Moneoy</td>
<td>Huntsman Cancer Institute, University of Utah</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Kunle</td>
<td>Otsente</td>
<td>The University of Chicago Medicine Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Iuya</td>
<td>Pal</td>
<td>Vanderbilt-Ingram Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Karolina</td>
<td>Palka</td>
<td>The Jackson Laboratory Cancer Center</td>
<td>Cue BioPharma, Merck</td>
<td>A,G,S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jennifer</td>
<td>Peger</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Tanyanika</td>
<td>Phillips</td>
<td>City of Hope Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Žižek</td>
<td>Ronai</td>
<td>Sanford Burnham Prebys Medical Discovery Institute</td>
<td>Pangea Therapeutics</td>
<td>A,G,S,O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ashley</td>
<td>Rosko</td>
<td>The Ohio State University Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Aril</td>
<td>Rustgi</td>
<td>Herbert Irving Comprehensive Cancer Center/Columbia University</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Yolanda</td>
<td>Sanchez</td>
<td>Dartmouth-Hitchcock Norris Cotton Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Julie</td>
<td>Schum</td>
<td>Vanderbilt-Ingram Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Norman</td>
<td>Sharpless</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Reuben</td>
<td>Shaw</td>
<td>Salk Institute Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Katherine</td>
<td>Shumate</td>
<td>UCSF Helen Diller Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>David</td>
<td>Smith</td>
<td>University of Michigan Rogel Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Mariana Carla</td>
<td>Stern</td>
<td>USC Norris Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Cornelia</td>
<td>Ulrich</td>
<td>Huntsman Cancer Institute, University of Utah</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Robert</td>
<td>Vanderheide</td>
<td>Abramson Cancer Center of the University of Pennsylvania</td>
<td>Children's Hospital Boston, licensed patents</td>
<td>O</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Jeff</td>
<td>Walker</td>
<td>Roswell Park Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Colin</td>
<td>Weckes</td>
<td>Massachusetts General Hospital</td>
<td>Ipsen Pharmaceuticals, Novartis, EM Diagnostics, Merck, Actuate, Dicerhema</td>
<td>C,G</td>
<td>Speaker</td>
</tr>
<tr>
<td>George</td>
<td>Weiner</td>
<td>Holden Comprehensive Cancer Center, University of Iowa</td>
<td>Regeneron, Checkmate Pharmaceuticals, Pfizer, LRECAP</td>
<td>C,G,S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jane</td>
<td>Welter</td>
<td>Mayo Clinic Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Robert</td>
<td>Winn</td>
<td>VCU Massey Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
</tbody>
</table>

Disclosure of Financial Relationships

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

Relationships are abbreviated as follows: E, Employee of listed company; G, Grant/research support recipient; A, Advisor or review panel member; C, Consultant; S, Stock shareholder; SB, Speakers’ bureau; H, Honoraria; O, Other.

Products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.
Advarra’s integrated solutions are designed to safeguard patients, empower clinical sites, ensure compliance, and optimize research performance. Together, we are working to make clinical research safer, smarter, and faster.

OnCore.
Streamline research operations with a comprehensive, proven, and standardized system built through collaboration with leading research organizations and used by more than 70% of NCI-designated cancer centers.

eREG.
Save time, improve workflows, and enhance regulatory compliance with the most comprehensive, integrated eRegulatory system available.

eConsent.
Keep patients engaged, ensure understanding, simplify oversight, and improve the overall consenting process at your center with Advarra eConsent.

Reviews.
Accelerate the review process and ensure appropriate participant and community protections with the specialized oncology expertise of Advarra’s IRB and IBC review services.

Molecular AI to Navigate mCRC Standard of Care Chemo Selection

Molecular AI is changing how we see cancer – and how we fight it.

Caris FOLFOXai™, from Caris Life Sciences®, is the first clinically validated, AI-powered molecular predictor of chemotherapy efficacy for mCRC patients. MI FOLFOXai™ is intended to gauge a mCRC patient’s likelihood of benefit from first-line treatment FOLFOX (plus bevacizumab) followed by FOLFIRI+BV, versus FOLFIRI+BV followed by FOLFOX+BV.

FOLFOXai™ demonstrated that the overall survival (OS) of patients treated in a manner consistent with the FOLFOXai prediction was 17.5 months longer (71%) than the OS of patients treated counter to the prediction.1

FOLFOXai™ comes standard with every Caris Molecular Intelligence™ colon cancer tumor profile at no additional cost, increased turnaround time or added specimen requirements. Where Molecular Science Meets Artificial Intelligence.

To order or learn more, please visit www.CarisLifeSciences.com/mi-folfoxai/ or contact your local Caris Representative.

Did COVID-19 leave you with registry backlogs and more questions than answers?

Ciox Cancer Registry Services can help!

With over 30 years of industry experience, Ciox provides knowledgeable CTRs to help with your organization's registry needs by offering:

• Accurate, timely data collection and submission
• Full cancer registry operations and workflow management
• Total outsource for data collection, registry oversight and accreditation support
• Consultative services provided by industry experts
• Education on topics such as cancer registry quality control, maximizing text and more

Learn more

Visit cioxhealth.com to learn how Ciox customizes cancer registry assistance to improve timely data collection and accreditation compliance.

Are you tired of fighting with messy binders, cluttered inboxes or misplaced documents?

Is the already heavy workload of tasks associated with the administration and management of regulatory and trial paperwork become even more compounded by COVID-19?

Do you want to reduce those tasks while improving your efficiency, compliance and transparency?

It's time to partner with Complion. Our cloud-based eReg solution enables you to:

✓ Quickly find the right document with better organized files, standard templates, and powerful keyword search.
✓ Reduce time managing PI delegation records, Safety Reports, CVs, Licenses and training with Part 11 compliant signatures and site-centric workflows.
✓ Eliminate printing and redundancy by connecting to existing email, CTMS, IRB or EMR systems without costly development or custom coding.
✓ Instantly collaborate across multiple sites and institutions.

Ready to learn more? Let's schedule a demo. Contact us at 800-615-9077 or info@complion.com.
Florence
Connecting sites and sponsors to bring treatments to market, faster.

Learn how Florence helps over 10,000 research teams across 44 countries streamline operations, turn on remote access, and take their day back from paper.

Florence eBinders, an eISF platform.
Florence eTMF
Florence eConsent
Florence eHub, a remote site access platform.

Huron understands cancer centers.
Addressing the unique needs of the world’s leading cancer centers:

- Enhance clinical research operations.
- Streamline research administration.
- Provide strategic advice.
- Prepare for National Cancer Institute designation.

huronconsultinggroup.com/insights/strategic-solutions-cancer-centers

© 2021 Huron Consulting Group Inc. and affiliates. 21-2725
Cancer Care Is Under Pressure

ECG’s payer strategies and operations expertise help cancer centers optimize financial performance and protect patient care.

To learn more visit ecgmc.com/cancer or call 1(800) 729-7635

nCoup proudly introduces the nCartes EHR to EDC platform to the AACI Community

For more information, please visit nCoup in the virtual exhibit hall or at ncartes.ncoup.com

nCoup Advancing Research Operations

WHY I’M A SITC Member

“One of the greatest benefits of SITC membership, is the opportunity to establish collaborations and partnerships that could help accelerate progress towards curing cancer with immunotherapy. In addition, the SITC provides a robust platform of mentorship for young investigators.”

Kunle Odunsi, MD, PhD
University of Chicago Medicine Comprehensive Cancer Center

Become a SITC member at sitcancer.org/join
WE'RE HIRING

Virtual Career Fair
October 22, 2021
8 a.m. - noon

The Clinical Research Services (CRS) department in the Sylvester Comprehensive Cancer Center is expanding and is hiring multiple Clinical Research, Regulatory and Research Nurse professionals.

Visit miami.edu/careers. (Job no. R100044788)

The Power of More.
More Patients.
More Trials.
More Time.

It's Time to Re-imagine Your Clinical Research Program
www.wcgclinical.com/optimize

WellSky

Streamline recruiting & patient scheduling, access data across multiple studies, and make quicker decisions with real-time analytics using

WellSky® Biotherapies

Learn more

AACI CCAF ANNUAL MEETING

2022

October 2–4, 2022
InterContinental at the Plaza | Kansas City

SAVE THE DATE